- Home
- ATXS vs CVAC Comparison
ATXS vs CVAC Comparison
Compare ATXS & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATXS | CVAC |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 1.1B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATXS | CVAC |
|---|---|---|
| Price | $12.99 | $4.31 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $24.33 | $6.83 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | N/A | ★ 0.94 |
| Revenue | $706,000.00 | ★ $83,000,117.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.71 |
| P/E Ratio | ★ N/A | $4.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.56 | $2.48 |
| 52 Week High | $13.29 | $5.72 |
Technical Indicators
Market Signals| Indicator | ATXS | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 62.11 | 31.72 |
| Support Level | $12.64 | $4.00 |
| Resistance Level | $13.00 | $4.36 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 62.96 | 23.66 |
Price Performance
Historical ComparisonAbout ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.